382 related articles for article (PubMed ID: 27733046)
1. Targeting of the Glutathione, Thioredoxin, and Nrf2 Antioxidant Systems in Head and Neck Cancer.
Roh JL; Jang H; Kim EH; Shin D
Antioxid Redox Signal; 2017 Jul; 27(2):106-114. PubMed ID: 27733046
[TBL] [Abstract][Full Text] [Related]
2. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
Roh JL; Kim EH; Jang H; Shin D
Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism.
Sobhakumari A; Love-Homan L; Fletcher EV; Martin SM; Parsons AD; Spitz DR; Knudson CM; Simons AL
PLoS One; 2012; 7(10):e48175. PubMed ID: 23118946
[TBL] [Abstract][Full Text] [Related]
4. Targeting redox homeostasis in rhabdomyosarcoma cells: GSH-depleting agents enhance auranofin-induced cell death.
Habermann KJ; Grünewald L; van Wijk S; Fulda S
Cell Death Dis; 2017 Oct; 8(10):e3067. PubMed ID: 28981107
[TBL] [Abstract][Full Text] [Related]
5. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
Shin D; Kim EH; Lee J; Roh JL
Redox Biol; 2017 Oct; 13():219-227. PubMed ID: 28582730
[TBL] [Abstract][Full Text] [Related]
6. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
Shin D; Kim EH; Lee J; Roh JL
Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of Radiation Response in Breast Cancer Stem Cells by Inhibition of Thioredoxin- and Glutathione-Dependent Metabolism.
Rodman SN; Spence JM; Ronnfeldt TJ; Zhu Y; Solst SR; O'Neill RA; Allen BG; Guan X; Spitz DR; Fath MA
Radiat Res; 2016 Oct; 186(4):385-395. PubMed ID: 27643875
[TBL] [Abstract][Full Text] [Related]
8. Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer.
Kim EH; Jang H; Shin D; Baek SH; Roh JL
Apoptosis; 2016 Nov; 21(11):1265-1278. PubMed ID: 27544755
[TBL] [Abstract][Full Text] [Related]
9. Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach.
Kiebala M; Skalska J; Casulo C; Brookes PS; Peterson DR; Hilchey SP; Dai Y; Grant S; Maggirwar SB; Bernstein SH
Exp Hematol; 2015 Feb; 43(2):89-99. PubMed ID: 25448488
[TBL] [Abstract][Full Text] [Related]
10. Enhanced thioredoxin, glutathione and Nrf2 antioxidant systems by safflower extract and aceglutamide attenuate cerebral ischaemia/reperfusion injury.
Zhang J; Zhou R; Xiang C; Fan F; Gao J; Zhang Y; Tang S; Xu H; Yang H
J Cell Mol Med; 2020 May; 24(9):4967-4980. PubMed ID: 32266795
[TBL] [Abstract][Full Text] [Related]
11. Dual pharmacological inhibition of glutathione and thioredoxin systems synergizes to kill colorectal carcinoma stem cells.
Tanaka G; Inoue K; Shimizu T; Akimoto K; Kubota K
Cancer Med; 2016 Sep; 5(9):2544-57. PubMed ID: 27485632
[TBL] [Abstract][Full Text] [Related]
12. A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition.
Kim EH; Jang H; Roh JL
Mol Cancer Ther; 2016 Nov; 15(11):2620-2629. PubMed ID: 27550943
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous inhibition of glutathione- and thioredoxin-dependent metabolism is necessary to potentiate 17AAG-induced cancer cell killing via oxidative stress.
Scarbrough PM; Mapuskar KA; Mattson DM; Gius D; Watson WH; Spitz DR
Free Radic Biol Med; 2012 Jan; 52(2):436-43. PubMed ID: 22100505
[TBL] [Abstract][Full Text] [Related]
14. Selective targeting of the cysteine proteome by thioredoxin and glutathione redox systems.
Go YM; Roede JR; Walker DI; Duong DM; Seyfried NT; Orr M; Liang Y; Pennell KD; Jones DP
Mol Cell Proteomics; 2013 Nov; 12(11):3285-96. PubMed ID: 23946468
[TBL] [Abstract][Full Text] [Related]
15. Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition.
Roh JL; Kim EH; Jang H; Shin D
Free Radic Biol Med; 2017 Mar; 104():1-9. PubMed ID: 28057599
[TBL] [Abstract][Full Text] [Related]
16. Hederagenin Induces Apoptosis in Cisplatin-Resistant Head and Neck Cancer Cells by Inhibiting the Nrf2-ARE Antioxidant Pathway.
Kim EH; Baek S; Shin D; Lee J; Roh JL
Oxid Med Cell Longev; 2017; 2017():5498908. PubMed ID: 29456786
[TBL] [Abstract][Full Text] [Related]
17. Resistance of neuroblastoma GI-ME-N cell line to glutathione depletion involves Nrf2 and heme oxygenase-1.
Furfaro AL; Macay JR; Marengo B; Nitti M; Parodi A; Fenoglio D; Marinari UM; Pronzato MA; Domenicotti C; Traverso N
Free Radic Biol Med; 2012 Jan; 52(2):488-96. PubMed ID: 22142473
[TBL] [Abstract][Full Text] [Related]
18. The thioredoxin antioxidant system.
Lu J; Holmgren A
Free Radic Biol Med; 2014 Jan; 66():75-87. PubMed ID: 23899494
[TBL] [Abstract][Full Text] [Related]
19. Adaptive response to GSH depletion and resistance to L-buthionine-(S,R)-sulfoximine: involvement of Nrf2 activation.
Lee HR; Cho JM; Shin DH; Yong CS; Choi HG; Wakabayashi N; Kwak MK
Mol Cell Biochem; 2008 Nov; 318(1-2):23-31. PubMed ID: 18587629
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of carboplatin-mediated lung cancer cell killing by simultaneous disruption of glutathione and thioredoxin metabolism.
Fath MA; Ahmad IM; Smith CJ; Spence J; Spitz DR
Clin Cancer Res; 2011 Oct; 17(19):6206-17. PubMed ID: 21844013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
